Chai Discovery
AI drug-discovery company building multimodal foundation models and computer-aided design tools for molecular structure prediction and de novo therapeutic design.
August 20261
Aug 20, 2026Chai Discovery partners with Bristol Myers SquibbPartnership
Chai Discovery and Bristol Myers Squibb announced a collaboration on AI-driven antibody discovery.
July 20263
Jul 15, 2026Chai Discovery partners with argenxPartnership
argenx gained early access to Chai's AI platform for de novo antibody discovery in immunology.
Jul 14, 2026Chai Discovery Series CFunding round
Chai Discovery raised a $400 million Series C led by Index Ventures.
Jul 13, 2026Chai Discovery partners with NovartisPartnership
Novartis gained access to Chai's AI design models and platform for therapeutic antibody discovery across multiple targets.
June 20262
Jun 4, 2026Chai Discovery licenses platform to PfizerPartnership
Pfizer licensed Chai's platform, including Chai-3, for AI-assisted molecular discovery.
Jun 4, 2026Chai-3 enters pharmaceutical partner useModel release
Chai disclosed Chai-3 as its most advanced molecular-design model through a licensing collaboration with Pfizer.
January 20261
Jan 9, 2026Chai Discovery partners with Eli LillyPartnership
Chai Discovery and Eli Lilly announced a collaboration to apply AI models to biologics discovery.
December 20251
Dec 15, 2025Chai Discovery Series BFunding round
Chai Discovery raised a $130 million Series B from General Catalyst and Oak HC/FT.
August 20251
Aug 6, 2025Chai Discovery Series AFunding round
Chai Discovery raised a $70 million Series A led by Menlo Ventures.
June 20252
Jun 30, 2025Chai-2 achieves double-digit de novo antibody hit ratesBenchmark result
Chai reported a 16% antibody binding rate, hits for half of tested targets, and a 68% wet-lab hit rate for miniprotein binders.
Jun 30, 2025Chai-2 unveiledModel release
Chai Discovery introduced a model family for zero-shot de novo antibody, nanobody, and miniprotein design.
September 20244
Sep 9, 2024Chai-1 reports state-of-the-art structure prediction resultsBenchmark result
Chai reported 77% PoseBusters success and 0.849 Cα LDDT on CASP15 protein monomers, alongside strong single-sequence multimer prediction.
Sep 9, 2024Chai-1 weights and inference code releasedOpen weights
Chai Discovery released Chai-1 model weights and inference code under Apache 2.0, including commercial use.
Sep 9, 2024Chai-1 releasedModel release
Chai Discovery released a multimodal foundation model for unified molecular structure prediction across proteins, small molecules, DNA, RNA, and covalent modifications.
Sep 9, 2024Chai Discovery seed roundFunding round
Chai Discovery raised approximately $30 million in seed funding led by Thrive Capital, OpenAI, and Dimension Capital.
* Market cap / valuation. Company values are AI-attributed: the latest market cap or valuation × the share attributed to AI (100% for pure AI companies). Methodology